The consortium is comprised of researchers from Inova, Roswell Park Comprehensive Cancer Center, the Mayo Clinic, and MD Anderson Cancer Center.
The Scientist writes that the announcement of Islamic State's Abu Bakr al-Baghdadi's death suggested that his identity might have been confirmed with rapid DNA testing.
The Broad Institute spinout will develop its CRISPR-based Sherlock platform for battlefield-ready diagnostics for infectious disease agents.
While the news of the BARDA contract drove a surge in T2's stock price, it was last month's NTAP decision that has company officials and analysts encouraged.
The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
According to Science, the independent Jason advisory group to the US Department of Defense has lost its contract.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.
The two-year contract will be used to develop a portable prototype to quickly identify critical infectious pathogens considered threatening to war combatants.
The consortium aims to identify tuberculosis protein targets and corresponding small molecule inhibitors that can be used to develop drugs to shorten therapy duration.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.